Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells

REFERENCES

• Abrieu, A., T. Brassac, S. Galas, D. Fisher, J. C. Labbe, and M. Doree. 1998. The Polo-like kinase Plx1 is a component of the MPF amplification loop at the G2/M-phase transition of the cell cycle in Xenopus eggs. J. Cell Sci. 111: 1751–1757.
   PubMed Web of Science ®Google Scholar
• Ankathil, R., N. Geetha, P. Remani, V. P. Gangadharan, G. R. Pillai, and M. K. Nair. 1996. Clinical implications of cytogenetic classification in adult acute lymphoblastic leukaemia patients. J. Cancer Res. Clin. Oncol. 122: 370–373.
   PubMedGoogle Scholar
• Belge, G., L. Roque, J. Soares, S. Bruckmann, B. Thode, E. Fonseca, A. Clode, S. Bartnitzke, S. Castedo, and J. Bullerdiek. 1998. Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. Cancer Genet. Cytogenet. 101: 42–48.
   PubMedGoogle Scholar
• Burns, T. F., E. J. Bernhard, and W. S. El-Deiry. 2001. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20: 4601–4612.
   PubMed Web of Science ®Google Scholar
• Burns, T. F., and W. S. El-Deiry. Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol. Ther., in press.
   Google Scholar
• Canman, C. E., A. C. Wolff, C. Y. Chen, A. J. Fornace, Jr., and M. B. Kastan. 1994. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res. 54: 5054–5058.
   PubMed Web of Science ®Google Scholar
• Chase, D., Y. Feng, B. Hanshew, J. A. Winkles, D. L. Longo, and D. K. Ferris. 1998. Expression and phosphorylation of fibroblast-growth-factor-inducible kinase (Fnk) during cell-cycle progression. Biochem. J. 333: 655–660.
   PubMedGoogle Scholar
• Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267: 1353–1356.
   PubMed Web of Science ®Google Scholar
• Dai, W., Q. Wang, and F. Traganos. 2002. Polo-like kinases and centrosome regulation. Oncogene 21: 6195–6200.
   PubMed Web of Science ®Google Scholar
• Di Leonardo, A., S. H. Khan, S. P. Linke, V. Greco, G. Seidita, and G. M. Wahl. 1997. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57: 1013–1019.
   PubMed Web of Science ®Google Scholar
• Donaldson, M. M., A. A. Tavares, I. M. Hagan, E. A. Nigg, and D. M. Glover. 2001. The mitotic roles of Polo-like kinase. J. Cell Sci. 114: 2357–2358.
   PubMed Web of Science ®Google Scholar
• Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
   PubMed Web of Science ®Google Scholar
• Fei, P., E. J. Bernhard, and W. S. El-Deiry. 2002. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62: 7316–7327.
   PubMed Web of Science ®Google Scholar
• Glover, D. M., I. M. Hagan, and A. A. Tavares. 1998. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 12: 3777–3787.
   PubMed Web of Science ®Google Scholar
• Hawkins, D. S., G. W. Demers, and D. A. Galloway. 1996. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56: 892–898.
   PubMed Web of Science ®Google Scholar
• Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253: 49–53.
   PubMed Web of Science ®Google Scholar
• Jang, Y. J., C. Y. Lin, S. Ma, and R. L. Erikson. 2002. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc. Natl. Acad. Sci. USA 99: 1984–1989.
   PubMed Web of Science ®Google Scholar
• Kadkol, S., J. Juang, and T. C. Wu. 2002. In situ hybridization in cancer and normal tissue. Humana Press, Totowa, N.J.
   Google Scholar
• Kauselmann, G., M. Weiler, P. Wulff, S. Jessberger, U. Konietzko, J. Scafidi, U. Staubli, J. Bereiter-Hahn, K. Strebhardt, and D. Kuhl. 1999. The polo-like protein kinases Fnk and Snk associate with a Ca2+- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J. 18: 5528–5539.
   PubMed Web of Science ®Google Scholar
• Khan, S. H., and G. M. Wahl. 1998. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58: 396–401.
   PubMedGoogle Scholar
• Kumagai, A., and W. G. Dunphy. 1996. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273: 1377–1380.
   PubMed Web of Science ®Google Scholar
• Lanni, J. S., and T. Jacks. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18: 1055–1064.
   PubMed Web of Science ®Google Scholar
• Lee, K. S., and R. L. Erikson. 1997. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell. Biol. 17: 3408–3417.
   PubMed Web of Science ®Google Scholar
• Li, B., B. Ouyang, H. Pan, P. T. Reissmann, D. J. Slamon, R. Arceci, L. Lu, and W. Dai. 1996. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J. Biol. Chem. 271: 19402–19408.
   PubMed Web of Science ®Google Scholar
• Li, F., G. Ambrosini, E. Y. Chu, J. Plescia, S. Tognin, P. C. Marchisio, and D. C. Altieri. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580–584.
   PubMed Web of Science ®Google Scholar
• Liu, X., and R. L. Erikson. 2002. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl. Acad. Sci. USA 99: 8672–8676.
   PubMed Web of Science ®Google Scholar
• Luo, X., Z. Tang, J. Rizo, and H. Yu. 2002. The Mad2 spindle checkpoint protein undergoes similar major conformational changes upon binding to either Mad1 or Cdc20. Mol. Cell 9: 59–71.
   PubMed Web of Science ®Google Scholar
• MacLachlan, T. K., K. Somasundaram, M. Sgagias, Y. Shifman, R. J. Muschel, K. H. Cowan, and W. S. El-Deiry. 2000. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol. Chem. 275: 2777–2785.
   PubMedGoogle Scholar
• Mark, J., R. Dahlenfors, and B. Wedell. 1997. Impact of the in vitro technique used on the cytogenetic patterns in pleomorphic adenomas. Cancer Genet. Cytogenet. 95: 9–15.
   PubMedGoogle Scholar
• McDonald, E. R. I., P. C. Chui, P. F. Martelli, D. T. Dicker, and W. S. El-Deiry. 2001. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J. Biol. Chem. 276: 14939–14945.
   PubMed Web of Science ®Google Scholar
• Meng, R. D., H. Shih, N. S. Prabhu, D. L. George, and W. S. El-Deiry. 1998. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin. Cancer Res. 4: 251–259.
   PubMedGoogle Scholar
• Minn, A. J., L. H. Boise, and C. B. Thompson. 1996. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10: 2621–2631.
   PubMed Web of Science ®Google Scholar
• Mundt, K. E., R. M. Golsteyn, H. A. Lane, and E. A. Nigg. 1997. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem. Biophys. Res. Commun. 239: 377–385.
   PubMed Web of Science ®Google Scholar
• Nigg, E. A. 1998. Polo-like kinases: positive regulators of cell division from start to finish. Curr. Opin. Cell Biol. 10: 776–783.
   PubMed Web of Science ®Google Scholar
• Ouyang, B., W. Li, H. Pan, J. Meadows, I. Hoffmann, and W. Dai. 1999. The physical association and phosphorylation of Cdc25C protein phosphatase by Prk. Oncogene 18: 6029–6036.
   PubMed Web of Science ®Google Scholar
• Ozoren, N., M. J. Fisher, K. Kim, C. X. Liu, A. Genin, Y. Shifman, D. T. Dicker, N. B. Spinner, N. A. Lisitsyn, and W. S. El-Deiry. 2000. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. 16: 917–925.
   PubMed Web of Science ®Google Scholar
• Potter, A. M., A. E. Watmore, P. Cooke, J. S. Lilleyman, and R. J. Sokol. 1981. Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br. J. Cancer 44: 51–54.
   PubMedGoogle Scholar
• Qian, Y. W., E. Erikson, C. Li, and J. L. Maller. 1998. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol. Cell. Biol. 18: 4262–4271.
   PubMed Web of Science ®Google Scholar
• Simmons, D. L., B. G. Neel, R. Stevens, G. Evett, and R. L. Erikson. 1992. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol. Cell. Biol. 12: 4164–4169.
   PubMed Web of Science ®Google Scholar
• Spankuch-Schmitt, B., G. Wolf, C. Solbach, S. Loibl, R. Knecht, M. Stegmuller, G. von Minckwitz, M. Kaufmann, and K. Strebhardt. 2002. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21: 3162–3171.
   PubMed Web of Science ®Google Scholar
• Stewart, Z. A., D. Mays, and J. A. Pietenpol. 1999. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 59: 3831–3837.
   PubMed Web of Science ®Google Scholar
• Stewart, Z. A., L. J. Tang, and J. A. Pietenpol. 2001. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20: 113–124.
   PubMed Web of Science ®Google Scholar
• Sunkel, C. E., and D. M. Glover. 1988. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. 89: 25–38.
   PubMed Web of Science ®Google Scholar
• Takimoto, R., T. K. MacLachlan, D. T. Dicker, Y. Niitsu, T. Mori, and W. S. El-Deiry. 2002. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol. Ther. 1: 177–186.
   PubMed Web of Science ®Google Scholar
• Teyssier, J. R., F. Liautaud-Roger, D. Ferre, M. Patey, and J. Dufer. 1990. Chromosomal changes in thyroid tumors. Relation with DNA content, karyotypic features, and clinical data. Cancer Genet. Cytogenet. 50: 249–263.
   PubMedGoogle Scholar
• Toyoshima-Morimoto, F., E. Taniguchi, N. Shinya, A. Iwamatsu, and E. Nishida. 2001. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410: 215–220.
   PubMed Web of Science ®Google Scholar
• Vikhanskaya, F., S. Vignati, P. Beccaglia, C. Ottoboni, P. Russo, M. D'Incalci, and M. Broggini. 1998. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp. Cell Res. 241: 96–101.
   PubMedGoogle Scholar
• Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70: 523–526.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408: 307–310.
   PubMed Web of Science ®Google Scholar
• Wahl, A. F., K. L. Donaldson, C. Fairchild, F. Y. Lee, S. A. Foster, G. W. Demers, and D. A. Galloway. 1996. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2: 72–79.
   PubMed Web of Science ®Google Scholar
• Wassmann, K., and R. Benezra. 2001. Mitotic checkpoints: from yeast to cancer. Curr. Opin. Genet. Dev. 11: 83–90.
   PubMedGoogle Scholar
• Wu, G. S., T. F. Burns, E. R. McDonald III, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y. Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu, and W. S. El-Deiry. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17: 141–143.
   PubMed Web of Science ®Google Scholar
• Wu, G. S., T. F. Burns, E. R. McDonald III, R. D. Meng, G. Kao, R. Muschel, T. Yen, and W. S. El-Deiry. 1999. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 18: 6411–6418.
   PubMed Web of Science ®Google Scholar
• Xie, S., H. Wu, Q. Wang, J. P. Cogswell, I. Husain, C. Conn, P. Stambrook, M. Jhanwar-Uniyal, and W. Dai. 2001. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J. Biol. Chem. 276: 43305–43312.
   PubMed Web of Science ®Google Scholar
• Xie, S., H. Wu, Q. Wang, J. Kunicki, R. O. Thomas, R. E. Hollingsworth, J. Cogswell, and W. Dai. 2002. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2. Cell Cycle 1: 424–429.
   PubMed Web of Science ®Google Scholar
• Yu, D., T. Jing, B. Liu, J. Yao, M. Tan, T. J. McDonnell, and M. C. Hung. 1998. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell 2: 581–591.
   PubMed Web of Science ®Google Scholar
• Yuan, J., A. Kramer, F. Eckerdt, M. Kaufmann, and K. Strebhardt. 2002. Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res. 62: 4186–4190.
   PubMed Web of Science ®Google Scholar